Improving Lives Through Biomedical Innovation


Paragon Biosciences identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies. Serving as a catalyst and advisor to our portfolio companies, we help people live longer, healthier lives.

 
PGBS-Homepage-Thumbnail.png
 

Our Focus

At Paragon Biosciences our philosophy is simple: start with what the patient needs, understand the science behind the disease and then launch companies completely focused on addressing unmet needs. After early-incubation, the companies we launch operate independently. Our approach accelerates the approval of important medicines.

More than 6,000 diseases today do not have a treatment available. We will make that number smaller, and help patients live longer, better lives.

 
 
 
 
Challenges which others have deemed unsolvable are the problems we are solving.
— JEFFREY S. ARONIN
 
PGBS-Jeff-Quote-Thumbnail.jpg
 

Portfolio Companies

Our investment portfolio of biopharmaceutical companies each specialize in a unique therapeutic area.

 
 
 
Paragon-BioSci-CastleCreek-Logo-New.jpg
 

Castle Creek Pharma

Castle Creek Pharma employs a unique strategy in selective asset identification and capital efficient development that is driving the company to become one of the industry’s most prolific developers of innovative and high potential late stage therapies for rare genetic dermatology conditions. For more information, please visit www.castlecreekpharma.com.


iStock-628504834.jpg
 

Harmony Biosciences

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on therapies for sleep and cognitive disorders, Harmony’s goal is to push the boundaries of what science can do to improve the lives of patients. For more information, please visit www.harmonybiosciences.com.


Paragon-BioSci-Skyline-Biosciences.png
 

Skyline Biosciences

Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant and malignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves. For more information, please visit www.skylinebiosciences.com.


Paragon-BioSci-Emalex-Biosciences.png
 

Emalex Biosciences

Emalex is committed to developing effective treatments for the Central Nervous System (CNS). Emalex’s focus is on making lives easier for the courageous people living with CNS disorders. For more information, please visit www.emalexbiosciences.com.


New-Company-Logos3.png
 

Incubating

Immunogenix

Developing the latest therapies for those living with serious immunology conditions.


Paragon-BioSci-Decade-Logo.jpg
 

Incubating

Decade Pharmaceuticals

Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.

 
 
 

Pipelines of Our Portfolio Companies

Paragon's portfolio companies have a diverse pipeline of investigational drugs, in four therapeutic areas.

 
Paragon_PipelineChart4-18-v9.gif
PGBS-BackgroundGrey.jpg
 

Our Process

We pride ourselves on investing in pharmaceutical compounds that our portfolio companies can develop into treatments for otherwise unmet patient needs. We embrace and overcome challenges to deliver important medicines.

 
ProcessChart.jpg
 

Our Responsibility

We believe it is our responsibility to contribute to organizations which improve the human experience, both globally and locally.

 
 
iStock-649871644.jpg

News

 

MAY 13, 2019

Jeff Aronin Receives Northern Illinois University’s 2019 Innovation and Entrepreneurship Award

Read More


APR 22, 2019

Paragon Biosciences Names James Robinson President and Chief Operating Officer

Read More


DEC 3, 2018

Jeff Aronin is Named Innovator of the Year by Best in Biz

Read More